Publications by authors named "Zhengzheng Ji"
Article Synopsis
- * A meta-analysis of 55 studies involving 7,180 HCC patients indicated that HBV infection did not significantly affect overall survival (OS) or progression-free survival (PFS) with ICIs, but HBV-infected patients may have a better tumor response.
- * High baseline HBV load is linked to worse survival outcomes, while antiviral therapy demonstrates improved prognostic outcomes for HCC patients treated with ICIs.
Article Synopsis
- Immune Checkpoint Inhibitors (ICIs) have transformed cancer treatment but can cause immune-related adverse events (irAEs), including pulmonary arterial hypertension (PAH).
- A male patient with intrahepatic cholangiocarcinoma and ankylosing spondylitis developed PAH after undergoing combined ICI therapy, showing fluctuating pulmonary artery pressures (PAP) during and after treatment.
- The patient was successfully treated with a combination of adalimumab, glucocorticoids, and immunosuppressants, indicating that DMARDs may help manage refractory PAH linked to irAEs.
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have been widely employed to improve the outcome of gastric cancer patients. In the present study, the impact of posttreatment growth hormone (GH) levels on the treatment efficacy of ICIs for advanced gastric cancer (AGC) patients was assessed.
Methods: Seventy-five AGC patients treated with anti-PD-1 antibodies at The Fourth Hospital of Hebei Medical University were involved.
Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients.
J Cancer Res Clin Oncol
July 2023
Purpose: Immune checkpoint inhibitors (ICIs) have improved the prognosis of cancer patients significantly with few predictive makers for treatment efficiency. Since interferon-gamma (IFN-γ) displayed its association with immunotherapy, we explored the correlation between IFN-γ and the efficacy of ICIs in tumor treatment.
Methods: We retrospectively examined cancer patients who received immune checkpoint inhibitors as first-line therapy at the Fourth Hospital of Hebei Medical University.